Next Science (ASX:NXS) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Next Science Dividend Payout Ratio?

Next Science's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for Next Science's Dividend Payout Ratio or its related term are showing as below:

ASX:NXS's Dividend Payout Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.34
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-08), the Dividend Yield % of Next Science is 0.00%.

Next Science's Dividends per Share for the months ended in Dec. 2023 was A$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Next Science Dividend Payout Ratio Historical Data

The historical data trend for Next Science's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Dividend Payout Ratio Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Next Science's Dividend Payout Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's Dividend Payout Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Next Science's Dividend Payout Ratio falls into.

Next Science Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Next Science's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-0.104
	=	N/A

Next Science's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.044
	=	N/A

Next Science (ASX:NXS) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Next Science Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Next Science's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (ASX:NXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines